Fair Accountability and Innovative Research Drug Pricing Act of 2019

4 steps remain before this bill could become law.

The record's latest action, on May 9, 2019: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

1. Clearing the committees it was referred to, and being scheduled for a floor vote
2. Passage by the Senate
3. Passage by the House
4. The President's signature. If the President vetoes it, two-thirds of both chambers must vote to override.

Civibrief does not forecast outcomes and this page has no opinion about this one. What the record supports is a base rate, which is a fact about the whole pile, not a prediction about this measure.

In the 116th Congress (2019-20), 344 of the 14,345 bills and joint resolutions introduced became law, about 2.4 percent. That count covers every measure at every stage, including the many that never left committee.

This one is not there yet: 4 steps are still outstanding, listed above.

No. No roll call in this Congress cites this measure. That is the ordinary outcome: most measures never reach a recorded floor vote, and a committee ends most of them simply by not acting.

A vote is not the only thing that happens to a measure. Hearings, markups, and referrals are all recorded actions, and none of them is a vote of the full chamber.

Tammy Baldwin (D-WI) introduced it on May 9, 2019, and 7 members have since signed on as cosponsors.

They come from both major parties: 2 Democrats, 4 Republicans, 1 independent.

Cosponsoring is a formal signature on the text. It is not a commitment to vote for the measure, it does not bind anyone's party, and a long list of cosponsors is a measure of attention rather than of prospects.

It was introduced on May 9, 2019, 2681 days ago. The most recent recorded action was 2681 days ago, on May 9, 2019.

Measures do not carry over. Anything the 116th Congress has not finished by January 3, 2021 dies when the term ends, and has to be introduced again from the start in the next Congress.